Compare LFMDP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMDP | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 384 | 30 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | LFMDP | SCLXW |
|---|---|---|
| Price | $23.58 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6K | ★ 1.9K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $18.50 | $0.04 |
| 52 Week High | $25.25 | $0.64 |
| Indicator | LFMDP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 44.41 |
| Support Level | $23.95 | $0.10 |
| Resistance Level | $24.19 | $0.18 |
| Average True Range (ATR) | 0.31 | 0.02 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 100.00 | 42.53 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.